* Abbvie receives CHMP positive opinion for Humira (adalimumab) for the treatment of pediatric patients, from six years of age, with moderately to severely active Crohn’s Disease
The post BRIEF-Abbvie receives CHMP positive opinion for Humira appeared first on NASDAQ.